Vaccine News and Research

Latest Vaccine News and Research

FDA approves expanded use of Gardasil 9 for adults aged 27 to 45 years

The U.S. Food and Drug Administration today approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use of the vaccine to include women and men aged 27 through 45 years.

6 Oct 2018

Researchers develop cancer vaccine platform to improve efficacy of oncolytic enveloped viruses

Researchers at the Faculty of Pharmacy have developed PeptiENV, a cancer vaccine platform, which can be used to improve the therapeutic efficacy of oncolytic enveloped viruses currently in clinical use.

6 Oct 2018

Researchers identify individual HPV types that are linked to HIV infection

An international research team led by a scientist at the University of California, Riverside, has for the first time identified individual types of the human papillomavirus, or HPV, that are specifically linked to HIV infection.

5 Oct 2018

Podcast: KHN’s ‘What the Health?’ Some things old, some things new

Congress passed major health-related legislation in time for the fiscal year, which began Monday, including a broad bill to address the opioid epidemic and a spending bill for the Department of Health and Human Services.

4 Oct 2018

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018.

4 Oct 2018

Viruses shown to cause bowel dysfunction and abdominal pain

Viruses known to target the central nervous system may also affect neurons of the digestive tract, causing bowel dysfunction and abdominal pain.

4 Oct 2018

Australia will soon become the first country to eradicate cervical cancer

According to an announcement from the International Papillomavirus Society, Australia could soon become the first country to eradicate cervical cancer.

4 Oct 2018

Two-pronged approach represents potential strategy for targeting latent reservoir of HIV

With more than 35 million people worldwide living with the virus and nearly 2 million new cases each year, the human immunodeficiency virus remains a major global epidemic.

4 Oct 2018

Changes in skin and lymphatic system due to age facilitate melanoma metastasis

Changes in the structure of the skin and the lymphatic system that occur with the natural aging process create permissive conditions for melanoma metastasis, according to two studies by The Wistar Institute.

3 Oct 2018

International conference features cutting-edge research studies on cancer immunotherapy

The Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, to be held in New York, Sept. 30-Oct. 3, will feature cutting-edge research studies from around the world that endeavor to answer urgent questions in the field of cancer immunotherapy to advance progress more rapidly for patients.

1 Oct 2018

Promising vaccine may provide new treatment option for patients with HER2-positive cancers

Treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers who had not previously been treated with a HER2-targeted therapeutic, according to data from a phase I clinical trial presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 30-Oct. 3.

30 Sep 2018

Synthetic DNA vaccine targets proteins overexpressed in several types of cancer

Scientists at The Wistar Institute have implemented a novel structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in several types of cancer.

28 Sep 2018

New combination therapy shows potential in treating incurable HPV-related cancers

A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to the human papilloma virus (HPV) in a phase II clinical trial led by investigators at The University of Texas MD Anderson Cancer Center and reported in JAMA Oncology.

28 Sep 2018

HPV vaccination offers best protection against cervical and genital cancers

In low-resource countries without well-developed screening programs, expanding access to human papilloma virus vaccination is the best means of preventing cervical cancer and other diseases caused by HPV infection, according to an editorial in the October special issue of the Journal of Lower Genital Tract Disease, official journal of ASCCP.

28 Sep 2018

Fina Biosolutions receives patent for expression and purification of the conjugate vaccine protein

Fina Biosolutions announces that the United States Patent and Trademark Office has issued a patent for expression and purification of the conjugate vaccine protein CRM197 in E. coli.

27 Sep 2018

New approach to vaccine development and improved surveillance could help target deadly diseases

Scientists hope that a new approach to vaccine development, combined with improved surveillance of potential future threats of outbreak, could help to massively reduce the impact of deadly diseases such as Ebola, Marburg and Lassa fever.

26 Sep 2018

Yellow fever virus can be transmitted via tiger mosquitoes, shows research

Since December 2016, Brazil has been grappling with its worst yellow fever outbreak for several decades. To date, there have been 2,043 human cases including 676 fatalities, mainly occurring in ten Brazilian states including Rio de Janeiro and São Paulo.

26 Sep 2018

Researchers develop promising allergy vaccine for hay fever

Using sugar molecules researchers from the University of Copenhagen have developed a new vaccine for hay fever that may reduce treatment times and increase the effect of treatments.

26 Sep 2018

Researchers aim to develop vaccine for 'traveler's diarrhea'

Every year, millions of people have vacations and business trips ruined when they succumb to "traveler's diarrhea" during their journeys. A major cause of traveler's diarrhea is bacteria called Enterotoxigenic E. coli, or ETEC.

26 Sep 2018

New TB vaccine effective in half of the population in phase II trials

GlaxoSmithKline has come up with an experimental vaccine against tuberculosis (TB) that has shown effective prevention of the infection in half of the population it has been administered to. This could be a breakthrough in preventing the killer disease say researchers since most of the recent vaccines developed against the disease have failed to show efficacy.

26 Sep 2018